Donald C. Anderson

MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX.

Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA.

Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ.

AureoGen, Inc. develops a novel genetic-engineering technology for the discovery and production of cyclic peptide based drugs. It focuses on chemical modification of cyclic peptide lead compounds, non-ribosomal peptide synthetases engineering, and chemo-enzymatic synthesis. The company was founded by Ake P. Elhammer and Jerry L. Slightom on August 12, 2003 and is headquartered in Kalamazoo, MI.